The IL-13/IL-4Rα axis is involved in tuberculosis-associated pathology

Journal of Pathology

Volumn 234, Issue 3, 2014, Pages 338-350

  Heitmann, Lisa ^a   Dar, Mahin Abad ^a   Schreiber, Tanja ^a   Erdmann, Hanna ^a   Behrends, Jochen ^a   Mckenzie, Andrew N J ^b   Brombacher, Frank ^c   Ehlers, Stefan ^a,d,e   Hölscher, Christoph ^a,d,e  

^a RESEARCH CENTER BORSTEL   (Germany)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF KIEL   (Germany)

^e German Center for Infection Research   (Germany)

Author keywords

Cytokines; Macrophages; Mice; Pathogenesis; Tuberculosis

Indexed keywords

COLLAGEN; INTERLEUKIN 13; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 4 RECEPTOR;

ACID FAST BACTERIUM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL IMMUNITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FLOW CYTOMETRY; HELPER CELL; HUMAN; IMMUNE RESPONSE; LUNG GRANULOMA; LUNG INJURY; MACROPHAGE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TUBERCULOSIS; WILD TYPE; ANIMAL; C57BL MOUSE; DISEASE MODEL; IMMUNOLOGY; LUNG TUBERCULOSIS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-13; MICE, INBRED C57BL; MICE, TRANSGENIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN-4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUBERCULOSIS, PULMONARY;

EID: 84907954260     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4399     Document Type: Article

References (57)

1. World Health Organization (WHO). Global Tuberculosis Control - Surveillance, Planning, Financing. WHO: Geneva, 2008.
2. Ehlers S, Hölscher C. DTH-associated pathology. In Microbiology and Microbial Infections, Kaufmann SH (ed.). Arnold: London, 2005; 705-720.
3. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19: 93-129.
4. Arriaga AK, Orozco EH, Aguilar LD, et al. Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp Immunol 2002; 128: 229-237.
5. Phyu S, Mustafa T, Hofstad T, et al. A mouse model for latent tuberculosis. Scand J Infect Dis 1998; 30: 59-68.
6. North RJ. Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis. Clin Exp Immunol 1998; 113: 55-58.
7. Jung YJ, LaCourse R, Ryan L, et al. Evidence inconsistent with a negative influence of T helper 2 cells on protection afforded by a dominant T helper 1 response against Mycobacterium tuberculosis lung infection in mice. Infect Immun 2002; 70: 6436-6443.
8. Hernandez-Pando R, Orozcoe H, Sampieri A, et al. Correlation between the kinetics of Th1,Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 1996; 89: 26-33.
9. Hernandez-Pando R, Pavon L, Arriaga K, et al. Pathogenesis of tuberculosis in mice exposed to lowand high doses of an environmental mycobacterial saprophyte before infection. Infect Immun 1997; 65: 3317-3327.
10. Roy E, Brennan J, Jolles S, et al. Beneficial effect of anti-interleukin-4 antibody when administered in a murine model of tuberculosis infection. Tuberculosis (Edinb) 2008; 88: 197-202.
11. Hernandez-Pando R, Aguilar D, Hernandez ML, et al. Pulmonary tuberculosis in BALB/c mice with non-functional IL-4 genes:changes in the inflammatory effects of TNFα and in the regulation of fibrosis. Eur J Immunol 2004; 34: 174-183.
12. Rook GAW, Hernández-Pando R, Dheda K, et al. IL-4 in tuberculosis:implications for vaccine design. Trends Immunol 2004; 25:483-488.
13. Buccheri S, Reljic R, Caccamo N, et al. IL-4 depletion enhances host resistance and passive IgA protection against tuberculosis infection in BALB/c mice. Eur J Immunol 2007; 37: 729-737.
14. Rook GA. Th2 cytokines in susceptibility to tuberculosis. Curr Mol Med 2007; 7: 327-337.
15. + T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J Infect Dis 2000; 181: 1194-1197.
16. Bhattacharyya S, Singla R, Dey AB, et al. Dichotomy of cytokine profiles in patients and high-risk healthy subjects exposed to tuberculosis. Infect Immun 1999; 67: 5597-5603.
17. Lin Y, Zhang M, Hofman FM, et al. Absence of a prominent Th2 cytokine response in human tuberculosis. Infect Immun 1996; 64:1351-1356.
18. Mohrs M, Ledermann B, Kohler G, et al. Differences between IL-4-and IL-4 receptor-α-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J Immunol 1999; 162:7302-7308.
19. Emson CL, Bell SE, Jones A, et al. Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13. J ExpMed 1998; 188:399-404.
20. Holscher C, Reiling N, Schaible UE, et al. Containment of aerogenic Mycobacterium tuberculosis infection in mice does not require MyD88 adaptor function for TLR2, -4 and -9. Eur J Immunol 2008; 38: 680-694.
21. Herbert DR, Holscher C, Mohrs M, et al. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 2004; 20: 623-635.
22. Holscher C, Holscher A, Ruckerl D, et al. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol 2005; 174: 3534-3544.
23. Behrends J, Renauld J-C, Ehlers S, et al. IL-22 is mainly produced by IFNγ-secreting cells but is dispensable for host protection against Mycobacterium tuberculosis infection. PloS One 2013; 8: e57379.
24. Schreiber T, Ehlers S, Heitmann L, et al. Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity. J Immunol 2009; 183: 1301-1302.
25. Anderson JM. Multinucleated giant cells. Curr Opin Hematol 2000; 7: 40-47.
26. Voskuil MI, Schnappinger D, Visconti KC, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J ExpMed 2003; 198: 705-713.
27. Peyron P, Vaubourgeix J, Poquet Y, et al. Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog 2008; 4: e1000204.
28. Aly S, Wagner K, Keller C, et al. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J Pathol 2006; 210:298-305.
29. Hesse M, Modolell M, La Flamme AC, et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol 2001; 167: 6533-6544.
30. Holscher C, Arendse B, Schwegmann A, et al. Impairment of alternative macrophage activation delays cutaneous leishmaniasis in nonhealing BALB/c mice. J Immunol 2006; 176: 1115-1121.
31. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
32. El Kasmi KC, Qualls JE, Pesce JT, et al. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol 2008; 9: 1399-1406.
33. Mattila JT, Ojo OO, Kepka-Lenhart D, et al. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol 2013; 191: 773-784.
34. Zea AH, Culotta KS, Ali J, et al. Decreased expression of CD3ζ and nuclear transcription factor-k B in patients with pulmonary tuberculosis:potential mechanisms and reversibility with treatment. J Infect Dis 2006; 194: 1385-1393.
35. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003; 21:425-456.
36. MacMicking JD, North RJ, LaCourse R, et al. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 1997; 94: 5243-5248.
37. Seah GT, Scott GM, Rook GA. Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J Infect Dis 2000; 181: 385-389.
38. Dheda K, Chang JS, Breen RA, et al. In vivo and in vitro studies of a novel cytokine, interleukin 4aδ2, in pulmonary tuberculosis. Am J Resp Crit Care Med 2005; 172: 501-508.
39. + T-cell subpopulation with memory phenotype in tuberculosis patients. Immunology 2004; 111:100-106.
40. Dlugovitzky D, Bottasso O, Dominino JC, et al. Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Resp Med 1999; 93: 557-562.
41. Sanchez FO, Rodriguez JI, Agudelo G, et al. Immune responsiveness and lymphokine production in patients with tuberculosis and healthy controls. Infect Immun 1994; 62: 5673-5678.
42. + T cells in response to Mycobacterium tuberculosis in tuberculosis patients. Tuberculosis (Edinb) 2002; 82: 7-13.
43. Sharma SK, Mitra DK, Balamurugan A, et al. Cytokine polarization in miliary and pleural tuberculosis. J Clin Immunol 2002; 22:345-352.
44. Marchant A, Amedei A, Azzurri A, et al. Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-α or interleukin-12. Am J Respir Cell Mol Biol 2001; 24: 187-194.
45. Lienhardt C, Azzurri A, Amedei A, et al. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol 2002; 32: 1605-1613.
46. Fenhalls G, Wong A, Bezuidenhout J, et al. In situ production of interferon-aγ, interleukin-4, and tumor necrosis factor-α mRNA in human lung tuberculous granulomas. Infect Immun 2000; 68:2827-2836.
47. Mazzarella G, Bianco A, Perna F, et al. T lymphocyte phenotypic profile in lung segments affected by cavitary and non-cavitary tuberculosis. Clin Exp Immunol 2003; 132: 283-288.
48. Tsai MC, Chakravarty S, Zhu G, et al. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol 2006; 8: 218-232.
49. Hunter RL, Jagannath C, Actor JK. Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs. Tuberculosis (Edinb) 2007; 87: 267-278.
50. Hernandez-Pando R, Schon T, Orozco EH, et al. Expression of inducible nitric oxide synthase and nitrotyrosine during the evolution of experimental pulmonary tuberculosis. Exp Toxicol Pathol 2001; 53: 257-265.
51. Kropf P, Fuentes JM, Fahnrich E, et al. Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. FASEB J 2005; 19: 1000-1002.
52. Hernandez-Pando R, Rook GA. The role of TNFα in T cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 1994; 82: 591-595.
53. Hunter RL, Olsen M, Jagannath C, et al. Trehalose 6,6′ -dimycolate and lipid in the pathogenesis of caseating granulomas of tuberculosis in mice. Am J Pathol 2006; 168: 1249-1261.
54. Rios-Barrera VA, Campos-Pena V, Aguilar-Leon D, et al. Macrophage and T lymphocyte apoptosis during experimental pulmonary tuberculosis: their relationship to mycobacterial virulence. Eur J Immunol 2006; 36: 345-353.
55. Pichugin AV, Yan BS, Sloutsky A, et al. Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am J Pathol 2009; 174: 2190-2201.
56. Reece ST, Loddenkemper C, Askew DJ, et al. Serine protease activity contributes to control of Mycobacterium tuberculosis in hypoxic lung granulomas in mice. J Clin Invest 2010; 120: 3365-3376.
57. Hernandez-Pando R, Orozco H, ArriagaK, et al. Analysis of the local kinetics and localization of interleukin-1α, tumour necrosis factor-α and transforming growth factor-β, during the course of experimental pulmonary tuberculosis. Immunology 1997; 90: 607-617.